Johnson & Johnson $JNJ Stock Position Lessened by Gen Wealth Partners Inc

Gen Wealth Partners Inc reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 14.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,832 shares of the company’s stock after selling 1,792 shares during the period. Johnson & Johnson comprises about 0.8% of Gen Wealth Partners Inc’s investment portfolio, making the stock its 28th biggest position. Gen Wealth Partners Inc’s holdings in Johnson & Johnson were worth $2,868,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cpwa LLC increased its holdings in shares of Johnson & Johnson by 36.5% during the third quarter. Cpwa LLC now owns 3,934 shares of the company’s stock worth $1,037,000 after buying an additional 1,051 shares in the last quarter. Global Wealth Management Investment Advisory Inc. raised its stake in shares of Johnson & Johnson by 2.7% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 27,401 shares of the company’s stock valued at $7,254,000 after acquiring an additional 721 shares during the last quarter. 71 West Capital Partners boosted its holdings in shares of Johnson & Johnson by 3.5% in the 3rd quarter. 71 West Capital Partners now owns 16,276 shares of the company’s stock worth $4,309,000 after acquiring an additional 544 shares in the last quarter. Flynn Zito Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 3.3% in the 3rd quarter. Flynn Zito Capital Management LLC now owns 3,310 shares of the company’s stock worth $876,000 after acquiring an additional 106 shares in the last quarter. Finally, Channel Wealth LLC boosted its holdings in shares of Johnson & Johnson by 1.1% in the 3rd quarter. Channel Wealth LLC now owns 4,687 shares of the company’s stock worth $1,241,000 after acquiring an additional 50 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Evercore set a $300.00 price objective on Johnson & Johnson in a research note on Tuesday, October 20th. The Goldman Sachs Group restated a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

JNJ opened at $281.86 on Tuesday. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.73. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The company’s 50 day simple moving average is $266.18 and its 200-day simple moving average is $248.62. The stock has a market capitalization of $678.53 billion, a P/E ratio of 42.71, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the business posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.